PureTech and its Founded Entities collaborate with an extensive network of scientists, clinicians and industry leaders, which has enabled us to consistently gain early access to discoveries well before the rest of the world reads about them and resulting in contributions to over 30 publications in top-tier science journals.
PureTech and its Founded Entities collaborate with an extensive network of scientists, clinicians and industry leaders, which has enabled us to consistently gain early access to discoveries well before the rest of the world reads about them and resulting in contributions to over 30 publications in top-tier science journals.
Bill Bradford
Former SVP InterMune; developed pirfenidone for the treatment of IPF
Bill Bradford
Former SVP InterMune; developed pirfenidone for the treatment of IPF
Vincent Cottin
Professor at Université Claude Bernard Lyon; Coordinator of Center for Rare Pulmonary Diseases at Louis Pradel Hospital; Section Editor of the European Respiratory Journal
Vincent Cottin
Professor at Université Claude Bernard Lyon; Coordinator of Center for Rare Pulmonary Diseases at Louis Pradel Hospital; Section Editor of the European Respiratory Journal
Kevin Flaherty
Professor at University of Michigan; PhIII trial of nintedanib in pfILD (NEJM)
Kevin Flaherty
Professor at University of Michigan; PhIII trial of nintedanib in pfILD (NEJM)
Toby Maher
Professor & Director of ILD at Keck School of Medicine, USC; PhII trial of pirfenidone in uILDs (Lancet RM)
Toby Maher
Professor & Director of ILD at Keck School of Medicine, USC; PhII trial of pirfenidone in uILDs (Lancet RM)
Paul Noble
Chair, Department of Medicine, Cedars-Sinai; results of two late-stage studies evaluating the effect of pirfenidone in patients w/ IPF (Lancet)
Paul Noble
Chair, Department of Medicine, Cedars-Sinai; results of two late-stage studies evaluating the effect of pirfenidone in patients w/ IPF (Lancet)
Marlies Wijsenbeek
Chair of Erasmus Medical Center ILD program; PI on study to identify disease progression in patients with newly diagnosed pfILDs
Marlies Wijsenbeek
Chair of Erasmus Medical Center ILD program; PI on study to identify disease progression in patients with newly diagnosed pfILDs
Michael A. Rogawski, MD, PhD
Professor of neurology and pharmacology at the University of California Davis
Michael A. Rogawski, MD, PhD
Professor of neurology and pharmacology at the University of California Davis
Steven Paul, MD
Founder and Chair of the Board of Directors at Seaport Therapeutics
Steven Paul, MD
Founder and Chair of the Board of Directors at Seaport Therapeutics
Stephen Brannan, MD
Neuroscience drug development expert, former Chief Medical Officer at Karuna Therapeutics (acquired by Bristol Myers Squibb)
Stephen Brannan, MD
Neuroscience drug development expert, former Chief Medical Officer at Karuna Therapeutics (acquired by Bristol Myers Squibb)
Murray Stein, MD, MPH, FRCPC
Distinguished Professor of Psychiatry and Public Health, UC San Diego
Murray Stein, MD, MPH, FRCPC
Distinguished Professor of Psychiatry and Public Health, UC San Diego
Samantha Meltzer-Brody, MD
Assad Meymandi Distinguished Professor and Chair of the Department of Psychiatry at the University of North Carolina at Chapel Hill
Samantha Meltzer-Brody, MD
Assad Meymandi Distinguished Professor and Chair of the Department of Psychiatry at the University of North Carolina at Chapel Hill
Julien Epps, PhD
Associate Professor in Signal Processing with the School of Electrical Engineering and Telecommunications at UNSW Australia
Julien Epps, PhD
Associate Professor in Signal Processing with the School of Electrical Engineering and Telecommunications at UNSW Australia
Maurizio Fava, MD
Executive Vice Chair of the Department of Psychiatry; Executive Director of the Massachusetts General Hospital Clinical Trials Network & Institute
Maurizio Fava, MD
Executive Vice Chair of the Department of Psychiatry; Executive Director of the Massachusetts General Hospital Clinical Trials Network & Institute
B. Brett Finlay, PhD
Howard Hughes Medical Institute Investigator; Professor at the University of British Columbia
B. Brett Finlay, PhD
Howard Hughes Medical Institute Investigator; Professor at the University of British Columbia
Adam Gazzaley, MD, PhD
Founding Director of the Neuroscience Imaging Center at the University of California, San Francisco
Adam Gazzaley, MD, PhD
Founding Director of the Neuroscience Imaging Center at the University of California, San Francisco
Kenya Honda, MD, PhD
Associate Professor of Immunology at the Graduate School of Medicine at the University of Tokyo
Kenya Honda, MD, PhD
Associate Professor of Immunology at the Graduate School of Medicine at the University of Tokyo
H. Robert Horvitz, PhD
David H. Koch Professor of Biology at Massachusetts Institute of Technology, Howard Hughes Medical Institute Investigator, and Neurobiologist (Neurology) at Massachusetts General Hospital
H. Robert Horvitz, PhD
David H. Koch Professor of Biology at Massachusetts Institute of Technology, Howard Hughes Medical Institute Investigator, and Neurobiologist (Neurology) at Massachusetts General Hospital
Dan Littman, MD, PhD
Howard Hughes Medical Institute Investigator, Professor of Molecular Immunology and Professor of Pathology and Microbiology at the NYU School of Medicine, member of the Board of Director's at Pfizer
Dan Littman, MD, PhD
Howard Hughes Medical Institute Investigator, Professor of Molecular Immunology and Professor of Pathology and Microbiology at the NYU School of Medicine, member of the Board of Director's at Pfizer
Ruslan Medzhitov, PhD
Howard Hughes Medical Institute Investigator; David W. Wallace Professor of Immunobiology at Yale University School of Medicine
Ruslan Medzhitov, PhD
Howard Hughes Medical Institute Investigator; David W. Wallace Professor of Immunobiology at Yale University School of Medicine
Siddhartha Mukherjee, MD, PhD
Assistant Professor of Medicine at Columbia University; Pulitzer Prize-winning author of Emperor of all Maladies
Siddhartha Mukherjee, MD, PhD
Assistant Professor of Medicine at Columbia University; Pulitzer Prize-winning author of Emperor of all Maladies
Christopher Porter, PhD
Director of the Monash Institute of Pharmaceutical Sciences (MIPS) at Monash University in Australia
Christopher Porter, PhD
Director of the Monash Institute of Pharmaceutical Sciences (MIPS) at Monash University in Australia
Alexander Rudensky, PhD
Howard Hughes Medical Institute Investigator, Tri-Institutional Professor at Memorial Sloan-Kettering Cancer Center, the Rockefeller University and Cornell University
Alexander Rudensky, PhD
Howard Hughes Medical Institute Investigator, Tri-Institutional Professor at Memorial Sloan-Kettering Cancer Center, the Rockefeller University and Cornell University
Maryanne Senna, MD
Board-Certified Dermatologist at Massachusetts General Hospital and Assistant Professor of Dermatology at Harvard Medical School; Founder and Co-Director of MGH Hair Loss Clinic
Maryanne Senna, MD
Board-Certified Dermatologist at Massachusetts General Hospital and Assistant Professor of Dermatology at Harvard Medical School; Founder and Co-Director of MGH Hair Loss Clinic